Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study

BMC Psychiatry

Table 2 Mean scores ± SD of the various measures of psychopathology and craving at the different time points of assessment (time 0 → time 2) in the control and the topiramate augmentation group

Variable (Mean ± SD)	Group	1^st Assessment (time 0)	2^nd Assessment (time 1)	3^rd Assessment (time 2)
HDRS
	Controls	38.7 ± 7.6	15.9 ± 8.6+	8.1 ± 6.6∞
	Topiramate	39.6 ± 5.5	12.5 ± 3.1*+	4.9 ± 3.1*∞
HARS
	Controls	30.5 ± 10.2	13.9 ± 6.7+	7.1 ± 6.2∞
	Topiramate	31.8 ± 5.3	10.9 ± 3.6*+	4.3 ± 3.8*∞
GAS
	Controls	46.7 ± 5.1	75.6 ± 9.3+	85.4 ± 8.5∞
	Topiramate	46.6 ± 4.7	74.3 ± 6.7+	84.3 ± 5.6∞
OCDS
	Controls	37.2 ± 8.3	17.3 ± 3.9+	13.3 ± 2.8∞
	Topiramate	37.6 ± 7.8	15.3 ± 3.9*+	10.3 ± 3.1**∞

Statistics: Between groups (independent samples t-test); within groups (RMANOVA)
*Significant difference between controls and topiramate augmentation group (< 0.05)
** Significant difference between controls and topiramate augmentation group (< 0.01)
+ Significant difference between 2^nd and 1^st assessment (< 0.01)
∞ Significant difference between 3rd and 2nd assessment (< 0.01)

ISSN: 1471-244X